Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Manuscript
  • Published:

TRAIL-induced eradication of primary tumour cells from multiple myeloma patient bone marrows is not related to TRAIL receptor expression or prior chemotherapy

Leukemia volume 15, pages 1650–1657 (2001)Cite this article

Abstract

TNF-related apoptosis-inducing ligand (TRAIL) shares significant homology with CD95 (Fas) ligand and has the ability to induce apoptosis in sensitive cells through a caspase-mediated pathway. We have evaluated the activity of purified human recombinant soluble TRAIL (S-TRAIL, comprising residues 114–281; Biomol, Plymouth Meeting, PA, USA) and a leucine zipper construct of TRAIL (LZ-TRAIL; Immunex, Seattle WA, USA) against myeloma cell lines NCI H929, U266, RPMI 8226, the FasL-sensitive Jurkat T cell ALL line, the lymphoblastoid cell line MC/CAR and primary tumour cells from 16 myeloma patients. Furthermore, we examined the relationship between TRAIL-induced apoptosis and TRAIL receptor expression utilising RT-PCR and flow cytometry. Two of three myeloma cell lines and Jurkat were TRAIL sensitive whereas MC/CAR was relatively resistant. Five of 16 (31%) primary tumours demonstrated ⩾20% reduction in myeloma cells following TRAIL incubation (20–59%). This did not correlate with prior therapy. Four cell lines (two sensitive) and five primary tumours (two sensitive) demonstrated mRNA expression of the intra-cellular death domain containing TRAIL-R1. Variable expression of the two decoy (TRAIL-R3 and R4) and soluble (osteoprotegerin) receptors was seen and this did not correlate with TRAIL resistance. We conclude that myeloma cell expression of death effector receptors for TRAIL is insufficient to confer sensitivity to TRAIL-induced apoptosis but that in a significant minority of patients, irrespective of prior therapy, tumour cells are sensitive to TRAIL. The further investigation of TRAIL as an adjunct to presently available therapies for myeloma is justified.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6

Similar content being viewed by others

References

  1. Hjorth M, Holmberg E, Rodjer S, Turesson I, Westin J, Wisloff F . Survival in conventionally treated younger (<60 years) multiple myeloma patients: no improvement during two decades. Nordic Myeloma Study Group (NMSG) Eur J Haematol 1999 62: 271–277

    Article  CAS  Google Scholar 

  2. Samson D, Gaminara E, Newland A, Van de Pette J, Kearney J, McCarthy D, Joyner M, Aston L, Mitchell T, Hamon M, Barrett AJ, Evans M . Infusion of vincristine and doxorubicin with oral dexamethasone as first-line therapy for multiple myeloma (see comments) Lancet 1989 2: 882–885

    Article  CAS  Google Scholar 

  3. Attal M, Harousseau JL, Stoppa AM, Sotto JJ, Fuzibet JG, Rossi JF, Casassus P, Maisonneuve H, Facon T, Ifrah N, Payen C, Bataille R . A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome (see comments) New Engl J Med 1996 335: 91–97

    Article  CAS  Google Scholar 

  4. Bjorkstrand B, Ljungman P, Bird JM, Samson D, Brandt L, Alegre A, Auzanneau G, Blade J, Brunet S, Carlson K . Autologous stem cell transplantation in multiple myeloma: results of the European Group for Bone Marrow Transplantation Stem Cells 1995 13: 140–146

    Article  Google Scholar 

  5. Gura T . How TRAIL kills cancer cells, but not normal cells (news; comment) Science 1997 277: 768

    Article  CAS  Google Scholar 

  6. Walczak H, Miller RE, Ariail K, Gliniak B, Griffith TS, Kubin M, Chin W, Jones J, Woodward A, Le T, Smith C, Smolak P, Goodwin RG, Rauch CT, Schuh JC, Lynch DH . Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo (see comments) Nat Med 1999 5: 157–163

    Article  CAS  Google Scholar 

  7. Ashkenazi A, Pai RC, Fong S, Leung S, Lawrence DA, Marsters SA, Blackie C, Chang L, McMurtrey AE, Hebert A, DeForge L, Koumenis IL, Lewis D, Harris L, Bussiere J, Koeppen H, Shahrokh Z, Schwall RH . Safety and antitumor activity of recombinant soluble Apo2 ligand J Clin Invest 1999 104: 155–162

    Article  CAS  Google Scholar 

  8. Jo M, Kim T, Seol D, Esplen JE, Dorko K, Billiar TR, Strom SC . Apoptosis induced in normal human hepatocytes by tumor necrosis factor-related apoptosis-inducing ligand Nat Med 2000 6: 564–567

    Article  CAS  Google Scholar 

  9. Pan G, O'Rourke K, Chinnaiyan AM, Gentz R, Ebner R, Ni J, Dixit VM . The receptor for the cytotoxic ligand TRAIL Science 1997 276: 111–113

    Article  CAS  Google Scholar 

  10. Pan G, Ni J, Wei YF, Yu G, Gentz R, Dixit VM . An antagonist decoy receptor and a death domain-containing receptor for TRAIL (see comments) Science 1997 277: 815–818

    Article  CAS  Google Scholar 

  11. Sheridan JP, Marsters SA, Pitti RM, Gurney A, Skubatch M, Baldwin D, Ramakrishnan L, Gray CL, Baker K, Wood WI, Goddard AD, Godowski P, Ashkenazi A . Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors (see comments) Science 1997 277: 818–821

    Article  CAS  Google Scholar 

  12. Walczak H, Degli-Esposti MA, Johnson RS, Smolak PJ, Waugh JY, Boiani N, Timour MS, Gerhart MJ, Schooley KA, Smith CA, Goodwin RG, Rauch CT . TRAIL-R2: a novel apoptosis-mediating receptor for TRAIL EMBO J 1997 16: 5386–5397

    Article  CAS  Google Scholar 

  13. MacFarlane M, Ahmad M, Srinivasula SM, Fernandes-Alnemri T, Cohen GM, Alnemri ES . Identification and molecular cloning of two novel receptors for the cytotoxic ligand TRAIL J Biol Chem 1997 272: 25417–25420

    Article  CAS  Google Scholar 

  14. Screaton GR, Mongkolsapaya J, Xu XN, Cowper AE, McMichael AJ, Bell JI . TRICK2, a new alternatively spliced receptor that transduces the cytotoxic signal from TRAIL Curr Biol 1997 7: 693–696

    Article  CAS  Google Scholar 

  15. Degli-Esposti MA, Smolak PJ, Walczak H, Waugh J, Huang CP, DuBose RF, Goodwin RG, Smith CA . Cloning and characterization of TRAIL-R3, a novel member of the emerging TRAIL receptor family J Exp Med 1997 186: 1165–1170

    Article  CAS  Google Scholar 

  16. Mongkolsapaya J, Cowper AE, Xu XN, Morris G, McMichael AJ, Bell JI, Screaton GR . Lymphocyte inhibitor of TRAIL (TNF-related apoptosis-inducing ligand): a new receptor protecting lymphocytes from the death ligand TRAIL J Immunol 1998 160: 3–6

    CAS  PubMed  Google Scholar 

  17. Degli-Esposti MA, Dougall WC, Smolak PJ, Waugh JY, Smith CA, Goodwin RG . The novel receptor TRAIL-R4 induces NF-kappaB and protects against TRAIL-mediated apoptosis, yet retains an incomplete death domain Immunity 1997 7: 813–820

    Article  CAS  Google Scholar 

  18. Marsters SA, Sheridan JP, Pitti RM, Huang A, Skubatch M, Baldwin D, Yuan J, Gurney A, Goddard AD, Godowski P, Ashkenazi A . A novel receptor for Apo2L/TRAIL contains a truncated death domain Curr Biol 1997 7: 1003–1006

    Article  CAS  Google Scholar 

  19. Emery JG, McDonnell P, Burke MB, Deen KC, Lyn S, Silverman C, Dul E, Appelbaum ER, Eichman C, DiPrinzio R, Dodds RA, James IE, Rosenberg M, Lee JC, Young PR . Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL J Biol Chem 1998 273: 14363–14367

    Article  CAS  Google Scholar 

  20. Griffith TS, Chin WA, Jackson GC, Lynch DH, Kubin MZ . Intracellular regulation of TRAIL-induced apoptosis in human melanoma cells J Immunol 1998 161: 2833–2840

    CAS  PubMed  Google Scholar 

  21. Snell V, Clodi K, Zhao S, Goodwin R, Thomas EK, Morris SW, Kadin ME, Cabanillas F, Andreeff M, Younes A . Activity of TNF-related apoptosis-inducing ligand (TRAIL) in haematological malignancies Br J Haematol 1997 99: 618–624

    Article  CAS  Google Scholar 

  22. Treon SP, Chauhan D, Raje N, Teoh G, Webb I, Anderson KC . Recombinant human TNF-related apoptosis inducing ligand (hu TRAIL) induces apoptosis of human multiple myeloma (MM) cells Blood 1998 10: 634a

    Google Scholar 

  23. Lincz LF, Spencer A . Freshly isolated myeloma cells show variable levels of apoptosis induced by recombinant human TNF-related apoptosis inducing ligand (TRAIL) 1st Annual Scientific Meeting of the Haematology Society of Australia and New Zealand Hobart 1999 p 175

    Google Scholar 

  24. Gazitt Y . TRAIL is a potent inducer of apoptosis in myeloma cells derived from multiple myeloma patients and is not cytotoxic to hematopoietic stem cells Leukemia 1999 13: 1817–1824

    Article  CAS  Google Scholar 

  25. Spector DL, Goldman RD, Leinwand LA . Culture and biochemical analysis of cells In Cells, A Laboratory Manual vol 1 Cold Spring Harbor Laboratory Press: New York 1998 pp 15.11–15.12

    Google Scholar 

  26. Spencer A, Xiu-Hua Y, Chase A, Goldman JM, Melo JV . BCR-ABL positive lymphoblastoid cells display limited proliferative capacity under in vitro culture conditions Br J Haematol 1996 94: 654–658

    Article  CAS  Google Scholar 

  27. Simonet WS, Lacey DL, Dunstan CR, Kelley M, Chang MS, Luthy R, Nguyen HQ, Wooden S, Bennett L, Boone T, Shimamoto G, DeRose M, Elliott R, Colombero A, Tan HL, Trail G, Sullivan J, Davy E, Bucay N, Renshaw-Gegg L, Hughes T . Osteoprotegerin: a novel secreted protein involved in the regulation of bone density Cell 1997 89: 309–319

    Article  CAS  Google Scholar 

  28. Griffith TS, Rauch CT, Smolak PJ, Waugh JY, boiani N, Lynch DH, Smith CA, Goodwin RG, Kubin MZ . Functional analysis of TRAIL receptors using monoclonal antibodies J Immunol 1999 162: 2597–2605

    CAS  PubMed  Google Scholar 

  29. Drexler HGD, Dirks WG, MacLeod RAF . False human hematopoietic cell lines: cross-contaminations and misinterpretations Leukemia 1999 13: 1601–1607

    Article  CAS  Google Scholar 

  30. Keane MM, Ettenberg SA, Nau MM, Russell EK, Lipkowitz S . Chemotherapy augments TRAIL-induced apoptosis in breast cell lines Cancer Res 1999 59: 734–741

    CAS  PubMed  Google Scholar 

  31. Clodi KW, Wimmer D, Li Y, Goodwin R, Jaeget U, Mann G, Gadner H, Younes A . TRAIL receptor expression and activity of TRAIL in primary B cell acute lymphoblastic leukemia (ALL) cells Blood 1999 94: 301a

    Google Scholar 

  32. Lenhoff S, Hjorth M, Holmberg E, Turesson I, Westin J, Nielsen JL, Wisloff F, Brinch L, Carlson K, Carlsson M, Dahl IM, Gimsing P, Hippe E, Johnsen H, Lamvik J, Lofvenberg E, Nesthus I, Rodjer S . Impact on survival of high-dose therapy with autologous stem cell support in patients younger than 60 years with newly diagnosed multiple myeloma: a population based study Blood 2000 95: 7–11

    CAS  PubMed  Google Scholar 

Download references

Acknowledgements

We would like to thank Immunex Corporation for kindly providing LZ-TRAIL and the TRAIL receptor antibodies.

Author information

Authors and Affiliations

  1. Hunter Haematology Research Group, Mater Misericordiae Hospital, NSW, Australia

    LF Lincz

  2. BMT Programme, Alfred Hospital, Melbourne, Victoria, Australia

    T-X Yeh & A Spencer

Authors
  1. LF Lincz
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. T-X Yeh
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. A Spencer
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Lincz, L., Yeh, TX. & Spencer, A. TRAIL-induced eradication of primary tumour cells from multiple myeloma patient bone marrows is not related to TRAIL receptor expression or prior chemotherapy. Leukemia 15, 1650–1657 (2001). https://doi.org/10.1038/sj.leu.2402251

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.leu.2402251

Keywords

This article is cited by

Search

Advanced search

Quick links